Trial Profile
A Randomized, Controlled, Double-blind, Phase 3 Trial to Evaluate the Effects of Maternal or Neonatal Pneumococcal Conjugate Vaccination on Pneumococcal Carriage in Infants up to Nine Months of Age - The PROPEL Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Tetanus toxoid (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms PROPEL
- 22 Oct 2020 Planned End Date changed from 1 Aug 2020 to 1 Dec 2020.
- 30 Jun 2020 Planned End Date changed from 1 Mar 2020 to 1 Aug 2020.
- 19 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.